Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg

被引：6
|
作者：
Cheung, Ka-Chun [1 ]
Wong, Lap-Gate [2 ]
Yeung, Yiu-Ming [1 ]
机构：
[1] Tuen Mun Hosp, Dept Med & Geriatr, Haematol Team, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Pathol, Hong Kong, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 03期
关键词：
D O I：
10.1080/10428190701882161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：596 / 597
页数：2
相关论文
共 50 条
  • [1] First clinical experiences with Gemtuzumab ozogamicin (GO, Mylotarg©) in CD33 positive relapsed/refractory leukemia in children
    Zwaan, CM
    Reinhardt, D
    Corbacioglu, S
    Jürgens, H
    Samuelsson, U
    Biondi, A
    Smith, OP
    Bökkerink, JPM
    Tissing, WJE
    Creutzig, U
    Kaspers, GJL
    LEUKEMIA, 2003, 17 (03) : 683 - 683
  • [2] FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
    Norsworthy, Kelly J.
    Ko, Chia-Wen
    Lee, Jee Eun
    Liu, Jiang
    John, Christy S.
    Przepiorka, Donna
    Farrell, Ann T.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (09): : 1103 - 1108
  • [3] Gemtuzumab-ozogamicin for Bridging to Transplant in Refractory/relapsed CD33 Positive Acute Leukemia - is it Worthwhile?
    Stadler, Michael
    Oberstaedt, Vanessa
    Dammann, Elke
    Hambach, Lothar
    Weissinger, Eva M.
    Lueck, Catherina
    Beutel, Gernot
    Eder, Matthias
    Ganser, Arnold
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 206 - 207
  • [4] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
    Chevallier, Patrice
    Mahe, Beatrice
    Garand, Richard
    Talmant, Pascaline
    Harousseau, Jean-Luc
    Delaunay, Jacques
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) : 209 - 211
  • [5] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
    Patrice Chevallier
    Beatrice Mahe
    Richard Garand
    Pascaline Talmant
    Jean-Luc Harousseau
    Jacques Delaunay
    International Journal of Hematology, 2008, 88 : 209 - 211
  • [6] Targeting CD33 for acute myeloid leukemia therapy
    Liu, Jingjing
    Tong, Jiayin
    Yang, Haiping
    BMC CANCER, 2022, 22 (01)
  • [7] Targeting CD33 for acute myeloid leukemia therapy
    Jingjing Liu
    Jiayin Tong
    Haiping Yang
    BMC Cancer, 22
  • [8] CD33 Targeted gd T cells for Treatment of Acute Myeloid Leukemia
    Boucher, Justin C.
    Austin, Anna L.
    Kostenko, Elena
    Reid, Kayla
    Nagy, Mate Z.
    Davila, Marco L.
    Guevara-Patino, Jose A.
    Bejanyan, Nelli
    MOLECULAR THERAPY, 2024, 32 (04) : 633 - 634
  • [9] Acute Lymphoblastic Leukemia (B-ALL) with co-expression of CD33 and CD13
    Kustiah
    Hernaningsih, Yetti
    BALI MEDICAL JOURNAL, 2023, 12 (01) : 983 - 986
  • [10] Clinical development of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia
    Larson, R. A.
    ANNALS OF HEMATOLOGY, 2006, 85 : 122 - 122
12345